MYOCD primarily functions as a transcriptional coactivator through interacting with SMAD3 directly, which promotes TGFB signaling pathway in the smooth muscle 39 and enhances TGFB-induced EMT and metastasis of NSCLC 40. Here, SMAD3 is linked to non-small cell lung carcinoma.